{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T15:14:36Z","timestamp":1776525276271,"version":"3.51.2"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Histochemica"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.acthis.2019.09.001","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T04:06:30Z","timestamp":1567829190000},"page":"151439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunohistochemical localization of afatinib in male rat intestines and skin after its oral administration"],"prefix":"10.1016","volume":"121","author":[{"given":"Yutaro","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Saita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rintaro","family":"Sogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Narisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.acthis.2019.09.001_bib0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/14656566.2013.758714","article-title":"Dacomitinib, a new therapy for the treatment of non-small cell lung cancer","volume":"14","author":"Brzezniak","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.acthis.2019.09.001_bib0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdermsci.2013.05.009","article-title":"Recent advances in the epidermal growth factor receptor\/ligand system biology on skin homeostasis and keratinocyte stem cell regulation","volume":"72","author":"Daisuke","year":"2013","journal-title":"J. Dermatol. Sci."},{"issue":"11","key":"10.1016\/j.acthis.2019.09.001_bib0015","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1128\/AAC.01267-12","article-title":"Immunocytochemistry for vancomycin using a monoclonal antibody that reveals accumulation of the drug in rat kidney and liver","volume":"56","author":"Fujiwara","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.acthis.2019.09.001_bib0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2217\/fon-2017-0636","article-title":"Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?","volume":"14","author":"Girard","year":"2018","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.acthis.2019.09.001_bib0025","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/0012-1606(83)90243-9","article-title":"Distribution and number of epidermal factor receptors in skin is related to epithelial cell growth","volume":"100","author":"Green","year":"1983","journal-title":"Dev. Biol."},{"key":"10.1016\/j.acthis.2019.09.001_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/567486","article-title":"Clinical efficacy and toxicity of anti-egfr therapy in common cancers","author":"Harandi","year":"2009","journal-title":"J. Oncol."},{"issue":"3","key":"10.1016\/j.acthis.2019.09.001_bib0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3747\/co.v18i3.877","article-title":"Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer","volume":"18","author":"Hirsh","year":"2011","journal-title":"Curr. Oncol."},{"issue":"5","key":"10.1016\/j.acthis.2019.09.001_bib0040","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/ncponc1087","article-title":"Drug insight: gastrointestinal and hepatic adverse effects of moleculartargeted agents in cancer therapy","volume":"5","author":"Loriot","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"8","key":"10.1016\/j.acthis.2019.09.001_bib0045","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1177\/33.8.3860561","article-title":"Detection of 5-bromodeoxyuridine (BrdUrd) incorporation by monoclonal antibodies: role of the DNA denaturation step","volume":"33","author":"Moran","year":"1985","journal-title":"J. Histochem. Cytochem."},{"issue":"50","key":"10.1016\/j.acthis.2019.09.001_bib0050","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1038\/onc.2016.170","article-title":"Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter","volume":"35","author":"Qu","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.acthis.2019.09.001_bib0055","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.acthis.2019.09.001_bib0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jpha.2018.09.002","article-title":"Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib","volume":"9","author":"Sogawa","year":"2019","journal-title":"J. Pharm. Anal."},{"issue":"2","key":"10.1016\/j.acthis.2019.09.001_bib0065","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.acthis.2019.09.001_bib0070","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.acthis.2019.09.001_bib0075","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00280-011-1803-9","article-title":"Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers","volume":"69","author":"Stopfer","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.acthis.2019.09.001_bib0080","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7","article-title":"Expression of the c-erbB-4\/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types","volume":"185","author":"Srinivasan","year":"1998","journal-title":"J. Pathol."},{"issue":"12","key":"10.1016\/j.acthis.2019.09.001_bib0085","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/ijc.30699","article-title":"Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats","volume":"140","author":"Van Sebille","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.acthis.2019.09.001_bib0090","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1124\/dmd.110.032292","article-title":"Characterization of HKI-272 covalent binding to human serum albumin Drug Metab","volume":"38","author":"Wang","year":"2010","journal-title":"Dispos."},{"issue":"5","key":"10.1016\/j.acthis.2019.09.001_bib0095","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.acthis.2019.09.001_bib0100","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1586\/era.13.31","article-title":"Diarrhoea associated with afatinib: an oral ErbB family blocker","volume":"13","author":"Yang","year":"2013","journal-title":"Expert Rev. Anticancer Ther."}],"container-title":["Acta Histochemica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065128119302351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065128119302351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T10:19:28Z","timestamp":1574849968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065128119302351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0065128119302351"],"URL":"https:\/\/doi.org\/10.1016\/j.acthis.2019.09.001","relation":{},"ISSN":["0065-1281"],"issn-type":[{"value":"0065-1281","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemical localization of afatinib in male rat intestines and skin after its oral administration","name":"articletitle","label":"Article Title"},{"value":"Acta Histochemica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acthis.2019.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151439"}}